SCHEMBL682800

SCHEMBL682800

Cn1c(=O)c2c(ncn2CC(O)CN2CCN(Cc3ccc(F)cc3)CC2)n(C)c1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 6/20 0.63
LMNA P02545 4/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
POLB P06746 2/20 0.58
HTR1A P08908 2/20 0.58
CHRM1 P11229 2/20 0.58
DRD2 P14416 2/20 0.58
ADRA1D P25100 2/20 0.58
ADRA1A P35348 2/20 0.58
ADRA1B P35368 2/20 0.58
MAPK1 P28482 1/20 0.53
TSHR P16473 1/20 0.52
GAA P10253 1/20 0.52
RAB9A P51151 1/20 0.52
ADORA2B P29275 1/20 0.51
ABCC8 Q09428 1/20 0.51
KCNJ11 Q14654 1/20 0.51
ALDH1A1 P00352 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683975 0.91 LMNA (0.65) RXFP1LMNASMN1; SMN2POLBMAPK1
SCHEMBL684000 0.90 SMN1; SMN2 (0.65) RXFP1LMNASMN1; SMN2POLBTSHR
SCHEMBL682806 0.89 LMNA (0.62) RXFP1LMNASMN1; SMN2POLBMAPK1
SCHEMBL684337 0.88 SMN1; SMN2 (0.68) RXFP1LMNASMN1; SMN2POLBMAPK1
SCHEMBL684336 0.87 RXFP1 (0.54) RXFP1LMNASMN1; SMN2POLBHTR1A
SCHEMBL682799 0.86 RXFP1 (0.60) RXFP1LMNASMN1; SMN2POLBHTR1A
SCHEMBL683590 0.85 SMN1; SMN2 (0.64) RXFP1LMNASMN1; SMN2POLBMAPK1
SCHEMBL684003 0.85 SMN1; SMN2 (0.68) RXFP1LMNASMN1; SMN2POLBMAPK1
SCHEMBL11123833 0.83 LMNA (0.75) RXFP1LMNASMN1; SMN2POLBGAA
SCHEMBL683977 0.83 SMN1; SMN2 (0.61) RXFP1LMNASMN1; SMN2POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF RXFP1 211/4885LMNA 2155/4885SMN1; SMN2 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.